Cancer Immunotherapy Utilized Bubble Liposomes and Ultrasound as Antigen Delivery System

Abstract

In dendritic cells (DCs)-based cancer immunotherapy, it is important to present the epitope peptide derived from tumor associated antigens (TAAs) on MHC class I in order to induce tumor specific cytotoxic T lymphocytes (CTLs). However, MHC class I molecules generally present the epitope peptides derived from endogenous antigens for DCs but not exogenous ones such as TAAs. Recently, we developed the novel liposomal bubbles (Bubble liposomes) encapsulating perfluoropropane nanobubbles. In this study, we attempted to establish the novel antigen delivery system to induce MHC class I presentation using the combination of ultrasound and Bubble liposomes. Using ovalbumin (OVA) as model antigen, the combination of Bubble liposomes and ultrasound exposure for the DC could induce MHC class I presentation. In addition, the viability of DCs was more than 80%. These results suggest that Bubble liposomes might be a novel ultrasound enhanced antigen delivery tool in DC-based cancer immunotherapy.

Ultrasound combined with microbubble mediated immunotherapy for tumor microenvironment

“…Experimental data suggest that tumor associated antigens released from cancer cells damaged by ultrasound irradiation are increased and recognized by DCs. In addition, the anti-tumorffect depends on the intensity of ultrasound exposure, which suggests that the degree of tumor damage may be related to the antitumor immune response (Oda et al, 2012;Xiong et al, 2020;Zhang et al, 2022). In Wang L's research, liposome microbubbles were used to deliver paclitaxel to glioblastoma xenografts in nude mice and were treated with low frequency ultrasound irradiation.…”